{"id":233462,"date":"2025-01-24T18:01:15","date_gmt":"2025-01-24T18:01:15","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=233462"},"modified":"2025-01-24T18:01:15","modified_gmt":"2025-01-24T18:01:15","slug":"actiunile-novo-nordisk-cel-mai-mare-producator-de-medicamente-din-europa-au-crescut-cu-peste-13-dupa-ce-compania-a-testat-cu-succes-un-nou-tratament-impotriva-obezitatii","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=233462","title":{"rendered":"Ac\u0163iunile Novo Nordisk, cel mai mare produc\u0103tor de medicamente din Europa, au crescut cu peste 13% dup\u0103 ce compania a testat cu succes un nou tratament \u00eempotriva obezit\u0103\u0163ii"},"content":{"rendered":"<p>\nAc\u0163iunile Novo Nordisk au crescut vineri dup\u0103 ce gigantul farmaceutic danez a raportat rezultate pozitive \u00een faza incipeint\u0103 a studiului pentru medicamentul de obezitate, amycretin, scrie CNBC.<\/p>\n<p>\nStudiul a ar\u0103tat c\u0103 tratamentul, administrat prin injec\u0163ie, a dus la o reducere medie a greut\u0103\u0163ii cu 22% la pacien\u0163ii obezi \u015fi supraponderali dup\u0103 36 de s\u0103pt\u0103m\u00e2ni. \u00cen compara\u0163ie, pacien\u0163ii trata\u0163i cu placebo au avut o cre\u015ftere a greut\u0103\u0163ii de 2,0% \u00een aceea\u015fi perioad\u0103.&nbsp;<\/p>\n<p>\nAc\u0163iunile Novo Nordisk au crescut cu p\u00e2n\u0103 la 13,65% la ora 12:50, ora Londrei.<\/p>\n<p>\nAc\u0163iunile companiei daneze Zealand Pharma, produc\u0103tor de medicamente pentru obezitate, au crescut, de asemenea, cu 4,7%, \u00een timp ce Eli Lilly, produc\u0103torul Zepbound, a \u00eenregistrat o u\u015foar\u0103 sc\u0103dere \u00een tranzac\u0163iile din pre-market.<\/p>\n<p>\nAmycretin \u0163inte\u015fte acela\u015fi hormon ca \u015fi Wegovy. \u00cen prezent, acesta este principalul medicament pentru obezitate al Novo Nordisk, \u00een timp ce Ozempic este tratamentul s\u0103u pentru diabet.&nbsp; &nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ac\u0163iunile Novo Nordisk au crescut vineri dup\u0103 ce gigantul farmaceutic danez a raportat rezultate pozitive \u00een faza incipeint\u0103 a studiului pentru medicamentul de obezitate, amycretin, scrie CNBC. Studiul a ar\u0103tat c\u0103 tratamentul, administrat prin injec\u0163ie, a dus la o reducere medie a greut\u0103\u0163ii cu 22% la pacien\u0163ii obezi \u015fi supraponderali dup\u0103 36 de s\u0103pt\u0103m\u00e2ni. \u00cen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[323,15494,16559],"class_list":["post-233462","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-medicamente","tag-novo-nordisk","tag-obezitate"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/233462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=233462"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/233462\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=233462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=233462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=233462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}